These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 22835520

  • 1. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.
    Kerkeni M, Saïdi A, Bouzidi H, Ben Yahya S, Hammami M.
    Microvasc Res; 2012 Nov; 84(3):378-83. PubMed ID: 22835520
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy.
    Ng ZX, Chua KH, Iqbal T, Kuppusamy UR.
    Int J Mol Sci; 2013 Apr 03; 14(4):7480-91. PubMed ID: 23552832
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes.
    Aubert CE, Michel PL, Gillery P, Jaisson S, Fonfrede M, Morel F, Hartemann A, Bourron O.
    Diabetes Metab Res Rev; 2014 Nov 03; 30(8):679-85. PubMed ID: 24449227
    [Abstract] [Full Text] [Related]

  • 15. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
    Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T.
    Metabolism; 2006 Sep 03; 55(9):1227-31. PubMed ID: 16919543
    [Abstract] [Full Text] [Related]

  • 16. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M, Franke S, Wolf G, Rohde RD, Stein G, Collaborative Study Group.
    Nephron Clin Pract; 2008 Sep 03; 108(4):c291-7. PubMed ID: 18434751
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children.
    Saito R, Araki S, Yamamoto Y, Kusuhara K.
    J Pediatr Endocrinol Metab; 2017 Jan 01; 30(1):63-69. PubMed ID: 27941172
    [Abstract] [Full Text] [Related]

  • 20. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
    Miura J, Yamagishi Si, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y.
    J Diabetes Complications; 2003 Jan 01; 17(1):16-21. PubMed ID: 12505751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.